Gastrointestinal stromal tumors: what do we know now?

Dedifferentiation in Gastrointestinal Stromal Tumor to an Anaplastic KIT-negative Phenotype

(2013) Cristina R. Antonescu et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Immunohistochemical Loss of Succinate Dehydrogenase Subunit A (SDHA) in Gastrointestinal Stromal Tumors (GISTs) Signals SDHA Germline Mutation

(2013) Markku Miettinen et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Anorectal gastrointestinal stromal tumors: a retrospective multicenter analysis of 15 cases emphasizing their high local recurrence rate and the need for standardized therapeutic approach

(2013) Abbas Agaimy et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Succinate Dehydrogenase Mutation Underlies Global Epigenomic Divergence in Gastrointestinal Stromal Tumor

(2013) J. Keith Killian et al.   Cancer Discovery

Loss of SDHA Expression Identifies SDHA Mutations in Succinate Dehydrogenase–deficient Gastrointestinal Stromal Tumors

(2012) Trisha Dwight et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors

(2012) Antoine Italiano et al.   BMC CANCER

Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era

(2012) P. A. Cassier et al.   CLINICAL CANCER RESEARCH

Expression of IGF-1 receptor in KIT/PDGF receptor-α wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction

(2012) Margherita Nannini et al.   Future Oncology

Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation ofSDHAin wild-type SDHB-negative gastrointestinal stromal tumors

(2012) Martin G. Belinsky et al.   GENES CHROMOSOMES & CANCER

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

(2012) Heikki Joensuu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors

(2012) Andrew J Wagner et al.   MODERN PATHOLOGY

SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors

(2012) Lindsey Oudijk et al.   MODERN PATHOLOGY

The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile

(2011) C. A. Eide et al.   CANCER RESEARCH

Frequency, phenotype, and genotype of minute gastrointestinal stromal tumors in the stomach: an autopsy study

(2011) Simone Muenst et al.   HUMAN PATHOLOGY

SDHA Loss-of-Function Mutations in KIT-PDGFRA Wild-Type Gastrointestinal Stromal Tumors Identified by Massively Parallel Sequencing

(2011) M. A. Pantaleo et al.   JNCI-Journal of the National Cancer Institute

Differential Properties of Current Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors

(2011) George D. Demetri   SEMINARS IN ONCOLOGY

Molecular and Clinicopathologic Characterization of Gastrointestinal Stromal Tumors (GISTs) of Small Size

(2010) Sabrina Rossi et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region

(2010) P A Cassier et al.   BRITISH JOURNAL OF CANCER

Gene Expression Profiling of Human Gastrointestinal Stromal Tumors According to Its Malignant Potential

(2010) Keun Hur et al.   DIGESTIVE DISEASES AND SCIENCES

Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients

(2010)   JOURNAL OF CLINICAL ONCOLOGY

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

(2010) Axel Le Cesne et al.   LANCET ONCOLOGY

ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours

(2010) Ping Chi et al.   NATURE

Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations

(2010) K. A. Janeway et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BRAFMutation Status in Gastrointestinal Stromal Tumors

(2009) Isabelle Hostein et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors

(2009) S. Romeo et al.   CLINICAL CANCER RESEARCH

Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene

(2009) Toshirou Nishida et al.   International Journal of Clinical Oncology

V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours

(2009) A Agaimy et al.   JOURNAL OF CLINICAL PATHOLOGY

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

(2009) Ronald P DeMatteo et al.   LANCET

Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib

(2009) Katherine A. Janeway et al.   PEDIATRIC BLOOD & CANCER

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

(2009) K. S. Gajiwala et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multiple Primary Sporadic Gastrointestinal Stromal Tumors in the Adult: An Underestimated Entity

(2008) D. Gasparotto et al.   CLINICAL CANCER RESEARCH

Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors

(2008) N. P. Agaram et al.   CLINICAL CANCER RESEARCH

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors

(2008) Narasimhan P. Agaram et al.   GENES CHROMOSOMES & CANCER

Neurofibromatosis type 1-related gastrointestinal stromal tumors: a special reference to loss of heterozygosity at 14q and 22q

(2008) Hidetaka Yamamoto et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group

(2008) Michael C. Heinrich et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

(2008) Michael C. Heinrich et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

(2008) B Liegl et al.   JOURNAL OF PATHOLOGY

Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases

(2008) Jerzy Lasota et al.   MODERN PATHOLOGY

Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression

(2008) Lei L Chen et al.   MODERN PATHOLOGY